Navigation Links
Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
Date:12/21/2010

e taking ACTOplus met or ACTOplus met XR.

ACTOS, ACTOplus met, ACTOplus met XR, and duetact are not for patients with type 1 "juvenile" diabetes or diabetic ketoacidosis.

Warning Specific to duetact: The chance of death from serious heart or blood vessel problems may be higher when using a sulfonylurea, an ingredient in duetact.

Precautions

ACTOS may cause low blood sugar when taken in combination with insulin or sulfonylureas. Lightheadedness, shakiness, dizziness, or hunger may mean that a patient's blood sugar is too low. Patients should talk to their doctor if low blood sugar is a problem for them.

Some people taking ACTOS, ACTOplus met, ACTOplus met XR, or duetact may experience mild-to-moderate swelling of legs and ankles, anemia, and weight gain.

If a patient is of childbearing age, they should talk to their doctor before taking ACTOS, ACTOplus met, ACTOplus met XR, or duetact, as this could increase their chance of becoming pregnant. Patients should talk to their doctor if they are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed.

Patients should not take ACTOS, ACTOplus met, ACTOplus met XR, or duetact if they have active liver disease. A doctor should perform a blood test to check for liver problems before a patient starts therapy and periodically thereafter. Patients should talk to their doctor immediately if they experience nausea, vomiting, stomach pain, unusual tiredness, loss of appetite, dark urine, or yellowing of the skin or eyes.

Some patients have experienced visual changes while taking ACTOS, ACTOplus met, ACTOplus met XR, or duetact. If a patient experiences vision problems, they should consult their doctor immediately.

Some people, particularly women, are at higher risk of having bone
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... and ZURICH , May 17, 2013 ... for Science, Technology and Research (A*STAR) and Switzerland,s ... healthy volunteer has been dosed in a Phase 1 clinical ... proprietary bacteriophage Qbeta virus-like particle (VLP) technology. In this first ... novel vaccine candidate and its potential to protect against H1N1 ...
(Date:5/16/2013)...  Nektar Therapeutics, (Nasdaq: NKTR ) President and ... is scheduled to present at the upcoming 2013 UBS Global ... the Sheraton New York Hotel on Tuesday, May 21, 2013 ... be accessible via a Webcast through a link posted in ... http://www.nektar.com . This Webcast will be available for replay ...
(Date:5/16/2013)... , May 16, 2013  Alere Inc. (NYSE: ... take charge of their health at home through the merger ... dividend of $3.00 per share on its Series B Convertible ... July 15, 2013 to holders of record of Series B ... Such payment will cover the amount of all ...
Breaking Medicine Technology:A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... and AIDS, LOS ANGELES, Nov. 28 , WHAT: AIDS VIGIL & ... children worldwide orphaned by AIDS each day, World Vision will ... concert with World Vision,s vigils in 16 ... a 24-hour period leading up to World AIDS Day. During this ...
... CHICAGO, Nov. 28 Having hypertension, or high blood,pressure, ... Alzheimer,s,disease, according to a new study presented today at ... (RSNA)., "While hypertension is not a cause of ... on the brain that increases its vulnerability,to the effects ...
Cached Medicine Technology:Voices to Unite in Los Angeles for 6,000 Children Orphaned Daily 2High Blood Pressure May Heighten Effects of Alzheimer's Disease 2
(Date:5/18/2013)... 18 (HealthDay News) -- Just a few extra cups ... of an autoimmune liver disease known as primary sclerosing ... the Mayo Clinic in Rochester, Minn., found that drinking ... the disease, which can lead to cirrhosis of the ... does not prove a cause-and-effect relationship. "While ...
(Date:5/18/2013)... 18, 2013 In a May 14, ... Double Mastectomy After Discovering Cancer Gene,” Fox News reported ... upon learning that she carried a gene that doctors ... cancer and a 50 percent risk of ovarian cancer ... on May 16, 2013 with a blog post entitled ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The Communities ... the special places we call home. These are the townships, ... They are the locations where the people are friendly and ... takes viewers off the highways and shares the best in ... both nations with an American sports and film celebrity. It ...
(Date:5/18/2013)... Washington DC (PRWEB) May 18, 2013 Family ... Best" designation for excellence by Follow Media Consulting, Inc. in ... award signifies the continued commitment and dedication of the areas ... lifestyle. , No one knows parenting better than Brenda Hyde, ... goal is to help parents know about the vast resources ...
(Date:5/18/2013)... 18, 2013 The “Sleep Apnea Diagnostic ... CPAP, Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal EPAP, ... 2017” analyzes and studies the major market drivers, restraints, ... of the World. , Browse , ... 16 Figures , 318 pagesand in-depth ...
Breaking Medicine News(10 mins):Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3
... Coalition for,Pulmonary Fibrosis (CPF) announced the appointment of ... has more than 25 years of experience,overseeing all ... in,leadership for non-profit foundations such as the CPF. ... including expanding CPF fundraising,capabilities and driving its overall ...
... Assume Key Management Posts as Senior Vice Presidents, ... (NYSE: AGP ) today announced the hiring ... key management positions: Linda,Whitley-Taylor has been named Executive ... AMERIGROUP as Senior Vice President, Senior,Litigation Counsel; and ...
... Robert A Weinberg is the first recipient of the science ... Georg and Eva Klein. The prize is awarded in person ... 29 January 2008. The prizewinner, who is to be a ... to Karolinska Institutet in Stockholm for two weeks to give ...
... In today,s volatile business,environment, unforeseen market shifts ... product forecasts, sales strategies and,development plans. By ... a high-functioning Competitive Intelligence group,can alert organizations ... warn,them about potential external risks., Competitive ...
... Collaboration with Harvard Medical International Provides ... Vital Global Health Information, BALTIMORE, Jan. 29 ... reach of their groundbreaking MEDEX,360m partnership with the launch ... and leisure travelers., Like the original MEDEX 360m ...
... side by side to equal the width of a human ... for administering medicines and other therapeutic agents to patients. But ... after they discharge their medical payloads has been a major ... months tracking the tiny tubes inside mice, have found some ...
Cached Medicine News:Health News:CPF Appoints Mishka Michon Chief Executive Officer 2Health News:AMERIGROUP Names Linda Whitley-Taylor as Executive Vice President, Associate Services 2Health News:AMERIGROUP Names Linda Whitley-Taylor as Executive Vice President, Associate Services 3Health News:Building and Sustaining Impactful Competitive Intelligence Organizations for Pharma 2Health News:MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 3
CPTMeister is a coding reference based on the Physicians' Current Procedural Terminology (CPT) codes developed by the American Medical Association. It is an iSilo document composed of more than 2,000...
The BluefishRx ICD-9 is a Palm OS code lookup tool which incorporates the ICD-9 code set with the full and short code descriptions. It includes a multi keyword search tool with a dictionary of over 2...
MD Coder v 6.0 is a charge capture for the Palm OS and Pocket PC operating systems. We have integrated the feedback from hospitals and physicians. MD Coder v 6.0 comes in three versions: Physician Ba...
Preferred Health Resourses Practice Management System is called Remedy. The PDA version is Remedy for the Palm. It is a data capture program for your medical billing....
Medicine Products: